It was certainly inevitable. In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology (ASCO) meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work isn’t finished.
Archive | Melanoma News
Lessons From Clinical Trial Setbacks Lead to Next Phase of Oncologic Advances
Posted in Melanoma News, Health Professionals, Of Interest
BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.
Posted in Melanoma News, Health Professionals, Clinical Trials
CheckMate-915 Trial Does Not Meet Co-Primary End Point of RFS for Melanoma
Updated results from the randomized, phase 3 CheckMate-915 trial found that nivolumab (Opdivo) plus ipilimumab (Yervoy) did not result in a statistically significant improvement in recurrence-free survival (RFS) in the intention-to-treat population of participants, according to Bristol Myers Squibb, the developer of the agents.
Posted in Melanoma News, Health Professionals, Clinical Trials
Melanoma Not Associated With Menopausal Hormone Therapy, Reproductive Factors
Melanoma is not associated with either reproductive factors or menopausal hormone therapy use, according to study data published in the British Journal of Dermatology.
Posted in Melanoma News, Health Professionals, Of Interest
